Roche and Zealand brought fresh attention to their amylin analog obesity franchises at ADA, highlighting tolerability considerations for petrelintide and signaling continued clinical development direction. The presentations underscored how safety profile discussions are shaping amylin-incretin combination roadmaps in obesity, where companies are increasingly calibrating efficacy against tolerability.